REQUEST A DEMO
Total
USD $0.00
Search more companies

China Resources Double-Crane Pharmaceutical Co.,Ltd. (China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: China Resources Double-Crane Pharmaceutical Co.,Ltd. Profile Updated: November 24, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Beijing Double-Crane Pharmaceutical Co., Ltd. was established in 1997. The major promoter to the establishment of the company is Beijing Pharmaceutical Plant, which was set up in 1939. The company's A shares were listed on Shanghai Stock Exchange on May 22, 1997. As a new & high-tech enterprise and the first approved GMP pharmaceutical company in China, the company is principally engaged in manufacture, processing and distribution of pharmaceuticals. Its products are classified into three categories: infusion solutions, cardiovascular drugs and endocrine secretion drugs, including vitamin E and C granules, ofloxacin (antimicrobial drug), levofloxacin mesylate (antimicrobial drugs) and metformin hydrochloride tablets, among others. By December 2006, it has annual sales about US$ 600 million, controlling shareholding in 17 subsidiaries and shares in 7 companies in most major cities throughout China. And its business covers areas of medical research, production, circulation and pharmaceutical equipment. DCPC has more than 10000 employees at present and a wide range of name brand products including Beijing Hypotensive No.0 Tablet, Ofloxacin, Levofloxacin, Wen Wei Shu granule, Yang Wei Shu granule, Beijing Royal Jelly etc. The company distributes its products primarily in domestic market.

Headquarters
No. 1, Lize East 2nd Road, Wangjing, Chaoyang District, Beijing
Beijing; Beijing; Postal Code: 100102

Contact Details: Purchase the China Resources Double-Crane Pharmaceutical Co.,Ltd. report to view the information.

Website: http://www.dcpc.com

Basic Information
Total Employees:
Purchase the China Resources Double-Crane Pharmaceutical Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the China Resources Double-Crane Pharmaceutical Co.,Ltd. report to view the information.
Registered Capital:
Purchase the China Resources Double-Crane Pharmaceutical Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the China Resources Double-Crane Pharmaceutical Co.,Ltd. report to view the information.
Incorporation Date:
May 16, 1997
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chairman of the Supervisory Board
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
60.21%
Purchase this report to view the information.
4.05%
Purchase this report to view the information.
2.12%
Purchase this report to view the information.
1.19%
Purchase this report to view the information.
0.66%
Subsidiaries
Anhui Chuangyang Shuanghe Pharmaceutical Packaging Co., Ltd.
Anhui Shuanghe Pharmaceutical Co., Ltd.
Beijing Secco Prosperity Pharmaceutical Co., Ltd.
Company Performance
Financial values in the chart are available after China Resources Double-Crane Pharmaceutical Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
13.28%
Total operating revenue
14.71%
Operating profit (EBIT)
24.59%
Net Profit (Loss) for the Period
31.56%
Total assets
9.95%
Total equity
-5.68%
Operating Profit Margin (ROS)
1.68%
Net Profit Margin
2.3%
Return on Equity (ROE)
3.67%
Debt to Equity Ratio
5.98%
Quick Ratio
-0.72%
Cash Ratio
-0.4%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?